Last reviewed · How we verify
RLD2002
RLD2002 is a small molecule that targets the SGLT2 receptor.
RLD2002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | RLD2002 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
RLD2002 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism of action is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
Key clinical trials
- A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (PHASE3)
- A Study to Evaluate the PK, Safety and Tolerability of HCP1803. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RLD2002 CI brief — competitive landscape report
- RLD2002 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI